Leiden, Netherlands

Johan Memelink


 

 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2008-2021

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Johan Memelink in Plant Metabolite Production

Introduction

Johan Memelink is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of plant science, particularly in the regulation of secondary metabolite production. With a total of three patents to his name, Memelink's work has implications for agricultural practices and biotechnological applications.

Latest Patents

Memelink's latest patents focus on means and methods for regulating secondary metabolite production in plants. One of his disclosures relates to chimeric genes encoding a bHLH protein of subfamily Iva, which comprises a bHLH domain. This innovation aims to enhance the regulation of biosynthesis and production of secondary metabolites in both plants and plant-derived cell cultures. Another patent also addresses similar themes, emphasizing the use of chimeric genes in the regulation of secondary metabolite production.

Career Highlights

Throughout his career, Johan Memelink has worked with prestigious institutions such as Universiteit Gent and Universiteit Leiden. His research has contributed to advancements in understanding plant biology and the manipulation of metabolic pathways for improved agricultural outcomes.

Collaborations

Memelink has collaborated with notable colleagues in his field, including Alain Goossens and Jan Mertens. These partnerships have fostered a collaborative environment that enhances research and innovation in plant metabolite production.

Conclusion

Johan Memelink's innovative work in the regulation of secondary metabolite production in plants showcases his expertise and dedication to advancing plant science. His contributions through patents and collaborations continue to influence the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…